Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $62.47 million versus the consensus estimate of $47.64 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.